trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Company profile
Ticker
TRVN
Exchange
Website
CEO
Carrie Bourdow
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
TRVN stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
22 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
1 Apr 24
DEFA14A
Additional proxy soliciting materials
21 Mar 24
8-K
Other Events
21 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Mar 24
DEF 14A
Definitive proxy
20 Feb 24
Transcripts
TRVN
Earnings call transcript
2023 Q3
14 Nov 23
TRVN
Earnings call transcript
2023 Q1
15 May 23
TRVN
Earnings call transcript
2022 Q4
30 Mar 23
TRVN
Earnings call transcript
2022 Q3
13 Nov 22
TRVN
Earnings call transcript
2022 Q3
9 Nov 22
TRVN
Earnings call transcript
2022 Q2
13 Aug 22
TRVN
Earnings call transcript
2022 Q1
13 May 22
TRVN
Earnings call transcript
2021 Q4
31 Mar 22
TRVN
Earnings call transcript
2021 Q3
15 Nov 21
TRVN
Earnings call transcript
2021 Q2
12 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.49 mm | 35.49 mm | 35.49 mm | 35.49 mm | 35.49 mm | 35.49 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.94 mm | 2.87 mm | 2.98 mm | 3.14 mm |
Cash used (since last report) | n/a | n/a | 20.29 mm | 19.82 mm | 20.51 mm | 21.67 mm |
Cash remaining | n/a | n/a | 15.21 mm | 15.68 mm | 14.98 mm | 13.82 mm |
Runway (months of cash) | n/a | n/a | 5.2 | 5.5 | 5.0 | 4.4 |
Institutional ownership, Q3 2023
3.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 5 |
Closed positions | 5 |
Increased positions | 6 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 281.80 mm |
Total shares | 696.83 k |
Total puts | 4.20 k |
Total calls | 50.00 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Renaissance Technologies | 177.45 k | $107.00 k |
BLK Blackrock | 112.02 k | $67.55 mm |
Geode Capital Management | 89.26 k | $53.85 mm |
Vanguard | 70.48 k | $42.50 mm |
Jump Financial | 44.40 k | $26.77 mm |
VIRT Virtu Financial | 33.15 k | $20.00 k |
Captrust Financial Advisors | 33.00 k | $19.90 mm |
STT State Street | 24.86 k | $14.99 mm |
FMR | 21.82 k | $13.16 mm |
HRT Financial | 19.08 k | $11.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Dec 23 | Robert T Yoder | Common Stock | Payment of exercise | Dispose F | No | No | 0.61 | 1,929 | 1.18 k | 158,877 |
14 Dec 23 | Robert T Yoder | Common Stock | Grant | Acquire A | No | No | 0.61 | 25,000 | 15.25 k | 160,806 |
14 Dec 23 | Robert T Yoder | Common Stock | Grant | Acquire A | No | No | 0.61 | 92,500 | 56.43 k | 135,806 |
14 Dec 23 | Bourdow Carrie L. | Common Stock | Payment of exercise | Dispose F | No | No | 0.61 | 7,123 | 4.35 k | 642,923 |
14 Dec 23 | Bourdow Carrie L. | Common Stock | Grant | Acquire A | No | No | 0.61 | 100,000 | 61.00 k | 650,046 |
14 Dec 23 | Bourdow Carrie L. | Common Stock | Grant | Acquire A | No | No | 0.61 | 370,000 | 225.70 k | 550,046 |
14 Dec 23 | Shin Barry | Common Stock | Payment of exercise | Dispose F | No | No | 0.61 | 3,616 | 2.21 k | 308,821 |
14 Dec 23 | Shin Barry | Common Stock | Grant | Acquire A | No | No | 0.61 | 50,000 | 30.50 k | 312,437 |
14 Dec 23 | Shin Barry | Common Stock | Grant | Acquire A | No | No | 0.61 | 185,000 | 112.85 k | 262,437 |
14 Dec 23 | Patricia M. Drake | Common Stock | Payment of exercise | Dispose F | No | No | 0.61 | 1,835 | 1.12 k | 107,078 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
19 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
HC Wainwright & Co. Maintains Buy on Trevena, Maintains $9 Price Target
2 Apr 24
Recap: Trevena Q4 Earnings
1 Apr 24